For pharmaceutical and clinical developments addressing highly unmet clinical needs, we rely on a consolidated network of academic and clinical collaborations and a top choice of industrial partners. For the benefit of patients, we strive to exploit the full potential of our unique IP portfolio with a stategic, diversified selection of short and long term development goals. We value a creative, out-of-the-box thinking and communication approach leading to disruptive innovation.

We at TRIMT are dedicated to those among us who are in need of hope and help, for they have been diagnosed with cancer.

We primarily focus our activities on a class of cellular biomarkers called integrins, in order to establish innovative clinical schemes for enhancing lifetimes and the quality of lives of patients with the most dreadful forms of this disease. Furthermore, we explore the fascinating areas of immune checkpoint inhibitors, small molecule drug conjugates (SMDCs) and intraoperative approaches using various modalities (optical, radioactive). Our expertise is focused on discovery, preclinical development and clinical translation.